STOCK TITAN

Replimune Announces Sander Slootweg will Depart from its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company’s upcoming annual general meeting.

“It has been a pleasure working with Sander since the inception of Replimune several years ago,” said Philip Astley-Sparke, CEO of Replimune. “We are grateful for Sander’s sage advice, expertise and Forbion’s support of Replimune, and the other directors and members of our executive team join me in wishing Sander continued success.”

“I am incredibly proud of being part of the board, and especially in what Replimune has accomplished since the company’s founding,” said Sander Slootweg, founder and managing partner at Forbion. “It was our belief from the start that tumor-directed oncolytic immunotherapy had immense potential to benefit patients in a variety of cancers, and I believe the company is well positioned to fulfill its promise.”

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Investor Inquiries
Chris Brinzey
Westwicke, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com


Replimune Group, Inc.

NASDAQ:REPL

REPL Rankings

REPL Latest News

REPL Stock Data

958.87M
70.94M
4.2%
92.18%
9.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WOBURN